Stoke Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 7, 2024
STOK$27.21-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of stockholders’ equity
| Common Stock · Additionalpaid-in capital · Accumulated other comprehensive gain (loss) · Accumulateddeficit · Total stockholders’equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2022 | 39,439,575 | $4 | $483,170 | $(1,175) | $(297,150) | $184,849 |
| Net loss | — | — | — | — | (22,545) | (22,545) |
| Unrealized gain on marketable securities | — | — | — | 577 | — | 577 |
| Stock-based compensation | — | — | 5,887 | — | — | 5,887 |
| Issuance of common stock upon exercise of stock options | 80,611 | — | 158 | — | — | 158 |
| Issuance of common stock related to employee stock purchase plan | 19,550 | — | 153 | — | — | 153 |
| Shares sold as part of controlled equity offering sales agreement | 4,635,353 | — | 44,743 | — | — | 44,743 |
| Balance as of March 31, 2023 | 44,175,089 | $4 | $534,111 | $(598) | $(319,695) | $213,822 |
| Net loss | — | — | — | — | (30,654) | (30,654) |
| Unrealized gain on marketable securities | — | — | — | 219 | — | 219 |
| Stock-based compensation | — | — | 6,760 | — | — | 6,760 |
| Issuance of common stock upon exercise of stock options | 27,908 | — | 48 | — | — | 48 |
| Balance as of June 30, 2023 | 44,202,997 | $4 | $540,919 | $(379) | $(350,349) | $190,195 |
| Balance as of December 31, 2023 | 45,918,233 | $5 | $561,433 | $(24) | $(401,849) | $159,565 |
| Net loss | — | — | — | — | (26,374) | (26,374) |
| Unrealized gain on marketable securities | — | — | — | 24 | — | 24 |
| Stock-based compensation | — | — | 5,410 | — | — | 5,410 |
| Issuance of common stock upon exercise of stock options | 270,032 | — | 250 | — | — | 250 |
| Issuance of common stock related to employee stock purchase plan | 37,542 | — | 168 | — | — | 168 |
| Shares sold as part of controlled equity offering sales agreement | 272,270 | — | 1,299 | — | — | 1,299 |
| Balance as of March 31, 2024 | 46,498,077 | $5 | $568,560 | $— | $(428,223) | $140,342 |
| Net loss | — | — | — | — | (25,695) | (25,695) |
| Unrealized gain on marketable securities | — | — | — | (15) | — | (15) |
| Stock-based compensation | — | — | 7,427 | — | — | 7,427 |
| Issuance of common stock upon exercise of stock options | 252,007 | — | 766 | — | — | 766 |
| Issuance of common stock and warrants upon follow-on offering, net of underwriting discounts, commissions and offering costs | 5,555,557 | — | 119,884 | — | — | 119,884 |
| Balance as of June 30, 2024 | 52,305,641 | $5 | $696,637 | $(15) | $(453,918) | $242,709 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.